10 results about "Cathepsin D" patented technology

The invention relates to synthetic peptides of no more than 20 amino acids in size useful in the treatment of cancer.

Anti-VEGF proteins, including the VEGF trap protein aflibercept, can be manufactured to have a low content of an aspartyl protease (e.g., a low content of cathepsin D), for example, less than 1 ppm of the aspartyl protease.

Anti-VEGF proteins including the VEGF trap protein aflibercept can be produced to have a low level of an aspartyl protease (e.g., a low level of cathepsin D), such as less than 1 ppm of the aspartyl protease.

The present invention relates to a peptide of 5 to 20 amino acids in size, preferably of 7 to 15 amino acids in size, wherein the peptide is (i) a fragment of an amino acid sequence NQGNQPQCRCLPGFLGDRCQYRQCSGYCEN (SEQ ID NO:1), said fragment comprising at least 5 consecutive amino acids of SEQ ID NO:1, or (ii) a functional variant of said fragment, preferably deriving from said fragment by deletion, insertion, and / or substitution of one or more amino acids, wherein the fragment or functional variant derived therefrom includes at least one of the amino acid R9, G16, D17, R18, C19, Q20, and Y21 of SEQ ID NO:1, and to its use as medicament or in diagnostic.

The application discloses a blood marker combination and kit for neurodegenerative diseases of lysosome function axis, and relates to the technical field of biomedical detection. The marker combination is composed of seven markers in three categories: glucocerebrosidase and cathepsin D; sphingolipids and gangliosides; and phosphorylated tau-217 protein, neurofilament light chain protein and glial fibrillary acidic protein. The application also provides an in-vitro diagnostic kit containing specific reagents for detecting the above markers, and constructs a risk assessment model based on a logistic regression or random forest algorithm. The marker combination and kit can be used for early screening, differential diagnosis, disease progression prediction and drug efficacy monitoring of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and neurogenic Gaucher disease, and have the advantages of high sensitivity, high specificity and minimally invasive detection.

The application discloses a kind of targeting cat calicivirus VP1-CDE protein chicken source single-chain antibody and its preparation and application, belong to biotechnology field.The single-chain antibody is selected from X2B2, X2E1 Or X2G5, its heavy chain variable region and light chain variable region amino acid sequence are respectively as shown in SEQ ID NO:1-6.The application is prokaryotic expression and purified VP1-CDE protein as antigen immunization chicken, amplifies VH And VL Gene and is spliced into scFv gene by (Gly4Ser) 3 linker, constructs library capacity not less than 5.25×10 7 CFU / mL phage display library, specific single-chain antibody clone is obtained by solid-phase panning, and its binding activity is verified by Western blot, ELISA, indirect immunofluorescence test after eukaryotic expression and purification.The results show that the three single-chain antibodies can specifically bind VP1-CDE protein and FCV virus particles, and there is no cross reaction, which provides key experimental materials for basic research of cat calicivirus, can be used for developing FCV rapid diagnostic reagent or kit, also provides candidate molecules for the development of FCV infection treatment drugs, and has important theoretical significance and application value.

The present invention relates to a peptide of from 5 to 20 amino acids, preferably from 7 to 15 amino acids, where said peptide is (i) a fragment of the amino acid sequence NQGNQPQCRCLPGFLGDRCQYRQCSGYCEN (SEQ ID NO: 1) comprising at least 5 consecutive amino acids of SEQ ID NO: 1, or (ii) a functional variant of said fragment, preferably derived from said fragment by deletion, insertion and / or substitution of one or more amino acids, wherein the fragment or the functional variant derived therefrom comprises at least one of the amino acids R9, G16, D17, R18, C19, Q20 and Y21 of SEQ ID NO: 1, and their use as a medicament or in diagnosis.

The invention discloses an SNP (Single Nucleotide Polymorphism) marker related to ovary maturation of freshwater shrimps, a detection primer and application of the SNP marker and the detection primer, and belongs to the technical field of biology. Aiming at the problem of breeding of late-maturing varieties of freshwater shrimps, the SNP marker provided by the invention is located in an exon region of a cathepsin D gene of the freshwater shrimps and is specifically located at the 15207bp position of the 5'end of a cathepsin D gene sequence, and a basic group at the position is C or T; the gonad development index of a CC genotype individual is obviously smaller than that of a TT genotype individual and a CT genotype individual (Plt; 0. 05), and the site does not change the composition of amino acid. The SNP marker provided by the invention not only can rapidly and stably identify the female shrimps with slow ovarian development, but also can be not limited by different development stages of the female freshwater shrimps, and can be used for early breeding of the freshwater shrimps, so that the parent screening efficiency is improved, and the breeding period is shortened.

Anti-VEGF proteins including the VEGF trap protein aflibercept can be produced to have a low level of an aspartyl protease (e.g., a low level of cathepsin D), such as less than 1 ppm of the aspartyl protease.

Anti-VEGF proteins including the VEGF trap protein aflibercept can be produced to have a low level of an aspartyl protease (e.g., a low level of cathepsin D), such as less than 1 ppm of the aspartyl protease.